Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Oct 26, 2022; 14(10): 561-564
Published online Oct 26, 2022. doi: 10.4330/wjc.v14.i10.561
Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors
Nenad Lakušić, Ivana Sopek Merkaš, Ana Marija Slišković, Dora Cerovec
Nenad Lakušić, Ivana Sopek Merkaš, Dora Cerovec, Department of Cardiology, Special Hospital for Medical Rehabilitation Krapinske Toplice, Krapinske Toplice 49217, Croatia
Nenad Lakušić, Department of Clinical Medicine, Faculty of Dental Medicine and Health Osijek, Osijek 31000, Croatia
Nenad Lakušić, Department of Internal Medicine, Family Medicine and History of Medicine, Faculty of Medicine Osijek, Osijek 31000, Croatia
Ana Marija Slišković, Department of Cardiology, University Hospital Centre Zagreb, Zagreb 10000, Croatia
Author contributions: Lakušić N, Sopek Merkaš I, Slišković AM were responsible for the conception and design of the manuscript, literature review, and they wrote the first original draft; Lakušić N and Cerovec D contributed in acquisition of data, analysis and interpretation, literature review, and making critical revisions related to the important intellectual content of the manuscript; all authors gave final approval for the final version of the article to be published.
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ivana Sopek Merkaš, MD, Doctor, Department of Cardiology, Special Hospital for Medical Rehabilitation Krapinske Toplice, 2 Gajeva, Krapinske Toplice 49217, Croatia. ivana.sopek@sbkt.hr
Received: July 10, 2022
Peer-review started: July 10, 2022
First decision: August 22, 2022
Revised: August 29, 2022
Accepted: September 21, 2022
Article in press: September 21, 2022
Published online: October 26, 2022
Core Tip

Core Tip: Sodium-glucose co-transporter 2 inhibitors have recently become an established treatment for most chronic heart failure (CHF) patients (with and without diabetes), and it is important for the cardiologist to know their side effects, including those that are rare, but serious, like euglycemic ketoacidosis. In this way, an unwanted outcome of CHF treatment can be avoided.